JAZZ Q1 2017 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$376M+11.9% YoY

Gross Profit

$351M93.3% margin

Operating Income

$136M36.2% margin

Net Income

$87M23.0% margin

EPS (Diluted)

$1.41

QoQ Revenue Growth

-5.2%

Cash Flow

Operating Cash Flow

$165M

Free Cash Flow

$161M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$4.8B

Total Liabilities

$2.8B

Stockholders' Equity

$2.0B

Cash & Equivalents

$347M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$376M	$336M	+11.9%
Gross Profit	$351M	$313M	+12.3%
Operating Income	$136M	$121M	+12.4%
Net Income	$87M	$74M	+16.7%

Revenue Segments

Xyrem

$272M73%

Erwinaze And Erwinase

$51M14%

Defitelio

$36M10%

Prialt

$8M2%

Other Products

$6M2%

Geographic Segments

UNITED STATES

$339M90%

Europe

$31M8%

Other Countries

$6M1%